In a phase 3, multicentre, open-label, randomised trial, trastuzumab deruxtecan (TD)
was superior to the standard of care trastuzumab emtansine in patients with HER2-positive
metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane [
[1]
]. Then, a phase 3 trial with HER2-low mBC patients (defined as 1+ and 2+ by immunohistochemistry
[IHC] or negative by in situ hybridisation [ISH]) who had received previous lines
of chemotherapy was performed [
[2]
]. In this trial TD resulted in significantly longer progression-free and overall
survival than the physician's choice of chemotherapy.- Modi S.
- Jacot W.
- Yamashita T.
- Sohn J.
- Vidal M.
- Tokunaga E.
- et al.
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
N Engl J Med. 2022 Jul 7; 387 (Epub 2022 Jun 5. PMID:35665782): 9-20https://doi.org/10.1056/NEJMoa2203690
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- DESTINY-Breast03 trial investigators. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N Engl J Med. 2022 Mar 24; 386 (PMID:35320644): 1143-1154https://doi.org/10.1056/NEJMoa2115022
- Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.N Engl J Med. 2022 Jul 7; 387 (Epub 2022 Jun 5. PMID:35665782): 9-20https://doi.org/10.1056/NEJMoa2203690
- HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer.Front Mol Biosci. 2022 Mar; 15 (eCollection 2022.PMID:35372498): 834651https://doi.org/10.3389/fmolb.2022.834651
- Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.Breast Cancer Res Treat. 2021 Jan; 185 (Epub 2020 Sep 27.PMID: 32980945): 183-194https://doi.org/10.1007/s10549-020-05935-5
- Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.Breast Cancer Res Treat. 2020 Aug; 183 (Epub 2020 Jul 1. PMID: 32613540): 137-144https://doi.org/10.1007/s10549-020-05746-8
- Evolution of low HER2 expression between early and advanced-stage breast cancer.Eur J Cancer. 2022; 163 (Epub 2022 Jan 13. PMID:35032815): 35-43https://doi.org/10.1016/j.ejca.2021.12.022
- HER2-Low breast cancer: pathological and clinical landscape.J Clin Oncol. 2020; 38 (10) (Epub 2020 Apr 24. PMID:32330069): 1951-1962https://doi.org/10.1200/JCO.19.02488
Article info
Publication history
Published online: November 13, 2022
Accepted:
October 14,
2022
Received:
August 5,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Evolution of low HER2 expression between early and advanced-stage breast cancerEuropean Journal of CancerVol. 163
- PreviewLow human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this biomarker during the course of disease is still poorly characterised, and controversial data exist on its prognostic implications.
- Full-Text
- Preview
- Response to letter entitled: Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”European Journal of CancerVol. 179
